The European Commission announced on Wednesday 10 November that it had signed its eighth advance purchase contract for Covid-19 vaccines. The contract covers the delivery to the EU in 2022 of 27 million doses of the candidate vaccine VLA2001 developed by the French pharmaceutical company Valneva (see EUROPE B12775A24).
The European Commission also has the option to request, during 2022, the delivery of an additional 33 million doses to be supplied by the company before the end of 2023.